Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 242

1.

NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomas-a study of 4569 cases.

Chou A, Fraser T, Ahadi M, Fuchs T, Sioson L, Clarkson A, Sheen A, Singh N, Corless CL, Gill AJ.

Mod Pathol. 2019 Dec 2. doi: 10.1038/s41379-019-0417-3. [Epub ahead of print]

PMID:
31792356
2.

Low-grade Osteosarcomatous Dedifferentiation of an Atypical Lipomatous Tumor in a Pediatric Patient.

Kukull BJ, Khalighi MA, Gundle KR, Hansford BG, Corless CL, Davis JL.

Pediatr Dev Pathol. 2019 Nov 18:1093526619889130. doi: 10.1177/1093526619889130. [Epub ahead of print]

PMID:
31739757
3.

A case of recurrent epilepsy-associated rosette-forming glioneuronal tumor with anaplastic transformation in the absence of therapy.

Halfpenny A, Ferris SP, Grafe M, Woltjer R, Selden N, Nazemi K, Perry A, Solomon DA, Gultekin SH, Moore S, Olson S, Lawce H, Lucas L, Corless CL, Wood MD.

Neuropathology. 2019 Oct;39(5):389-393. doi: 10.1111/neup.12586. Epub 2019 Aug 21.

4.

Loss of the PTCH1 tumor suppressor defines a new subset of plexiform fibromyxoma.

Banerjee S, Corless CL, Miettinen MM, Noh S, Ustoy R, Davis JL, Tang CM, Yebra M, Burgoyne AM, Sicklick JK.

J Transl Med. 2019 Jul 30;17(1):246. doi: 10.1186/s12967-019-1995-z.

5.

Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs).

Heinrich MC, Patterson J, Beadling C, Wang Y, Debiec-Rychter M, Dewaele B, Corless CL, Duensing A, Raut CP, Rubin B, Ordog T, van de Rijn M, Call J, Mühlenberg T, Fletcher JA, Bauer S.

Clin Sarcoma Res. 2019 Mar 5;9:3. doi: 10.1186/s13569-019-0112-7. eCollection 2019.

6.

Circulating tumor DNA dynamics using patient-customized assays are associated with outcome in neoadjuvantly treated breast cancer.

Butler TM, Boniface CT, Johnson-Camacho K, Tabatabaei S, Melendez D, Kelley T, Gray J, Corless CL, Spellman PT.

Cold Spring Harb Mol Case Stud. 2019 Apr 1;5(2). pii: a003772. doi: 10.1101/mcs.a003772. Print 2019 Apr.

7.

Implementing a comprehensive translational oncology platform: from molecular testing to actionability.

Mitri ZI, Parmar S, Johnson B, Kolodzie A, Keck JM, Morris M, Guimaraes AR, Beckett BR, Borate U, Lopez CD, Kemmer KA, Alumkal JJ, Beer TM, Corless CL, Mills GB, Gray JW, Bergan RC.

J Transl Med. 2018 Dec 14;16(1):358. doi: 10.1186/s12967-018-1733-y.

8.

Colorectal Cancer-Associated Spontaneous Tumor Lysis Syndrome: a Case Report and Review of the Current Literature.

Kearney MR, Chen EY, Stenzel P, Corless CL, Deloughery TG, Zivney M, Lopez CD.

J Gastrointest Cancer. 2019 Sep;50(3):668-673. doi: 10.1007/s12029-018-0102-7. No abstract available.

PMID:
29691710
9.

Gastrointestinal stromal tumours of the oesophagus: a clinicopathological and molecular analysis of 27 cases.

Kang G, Kang Y, Kim KH, Ha SY, Kim JY, Shim YM, Heinrich MC, Kim KM, Corless CL.

Histopathology. 2017 Nov;71(5):805-812. doi: 10.1111/his.13292. Epub 2017 Sep 6.

PMID:
28644569
10.

Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions.

Gay ND, Wang Y, Beadling C, Warrick A, Neff T, Corless CL, Tolba K.

J Thorac Oncol. 2017 Aug;12(8):e107-e110. doi: 10.1016/j.jtho.2017.04.025. Epub 2017 May 10. No abstract available.

11.

Defining the Impact of Adjuvant Therapy in Molecularly Defined Subsets of Gastrointestinal Stromal Tumor : From Lumping to Splitting.

Heinrich MC, Corless CL, Demetri GD.

JAMA Oncol. 2017 May 1;3(5):597-599. doi: 10.1001/jamaoncol.2016.5740. No abstract available.

PMID:
28334361
12.

Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors.

Bannon AE, Klug LR, Corless CL, Heinrich MC.

Expert Rev Mol Diagn. 2017 May;17(5):445-457. doi: 10.1080/14737159.2017.1308826. Epub 2017 Mar 27. Review.

PMID:
28317407
13.

MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation.

Schaefer IM, Wang Y, Liang CW, Bahri N, Quattrone A, Doyle L, Mariño-Enríquez A, Lauria A, Zhu M, Debiec-Rychter M, Grunewald S, Hechtman JF, Dufresne A, Antonescu CR, Beadling C, Sicinska ET, van de Rijn M, Demetri GD, Ladanyi M, Corless CL, Heinrich MC, Raut CP, Bauer S, Fletcher JA.

Nat Commun. 2017 Mar 8;8:14674. doi: 10.1038/ncomms14674.

14.

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.

Heinrich MC, Rankin C, Blanke CD, Demetri GD, Borden EC, Ryan CW, von Mehren M, Blackstein ME, Priebat DA, Tap WD, Maki RG, Corless CL, Fletcher JA, Owzar K, Crowley JJ, Benjamin RS, Baker LH.

JAMA Oncol. 2017 Jul 1;3(7):944-952. doi: 10.1001/jamaoncol.2016.6728. Erratum in: JAMA Oncol. 2017 Jul 1;3(7):1002.

15.

Molecular Testing in Patients With Castration-Resistant Prostate Cancer and Its Impact on Clinical Decision Making.

Tao DL, Bailey S, Beer TM, Foss E, Beckett B, Fung A, Foster BR, Guimaraes A, Cetnar JP, Graff JN, Eilers KM, Small EJ, Corless CL, Thomas GV, Alumkal JJ.

JCO Precis Oncol. 2017;1. doi: 10.1200/PO.16.00067. Epub 2017 Jun 28.

16.

FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors.

Shi E, Chmielecki J, Tang CM, Wang K, Heinrich MC, Kang G, Corless CL, Hong D, Fero KE, Murphy JD, Fanta PT, Ali SM, De Siena M, Burgoyne AM, Movva S, Madlensky L, Heestand GM, Trent JC, Kurzrock R, Morosini D, Ross JS, Harismendy O, Sicklick JK.

J Transl Med. 2016 Dec 14;14(1):339.

17.

Next-Generation Sequencing in Cancer Diagnostics.

Corless CL.

J Mol Diagn. 2016 Nov;18(6):813-816. doi: 10.1016/j.jmoldx.2016.08.002. Epub 2016 Sep 21.

PMID:
27664753
18.

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.

Ben-Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Yap JT, Van den Abbeele AD, Solomon SM, Fletcher JA, Demetri GD, George S.

Ann Oncol. 2016 Sep;27(9):1794-9. doi: 10.1093/annonc/mdw228. Epub 2016 Jul 1.

19.

IGF1R as a Key Target in High Risk, Metastatic Medulloblastoma.

Svalina MN, Kikuchi K, Abraham J, Lal S, Davare MA, Settelmeyer TP, Young MC, Peckham JL, Cho YJ, Michalek JE, Hernandez BS, Berlow NE, Jackson M, Guillaume DJ, Selden NR, Bigner DD, Nazemi KJ, Green SC, Corless CL, Gultekin S, Mansoor A, Rubin BP, Woltjer R, Keller C.

Sci Rep. 2016 Jun 3;6:27012. doi: 10.1038/srep27012.

20.

Discordant Mutations in Paired Primary and Metastatic Endometrial Adenocarcinomas Identified by Semiconductor-Based Sequencing for Rapid Cancer Genotyping.

Bergstrom CP, Geest K, O'Gara R, Corless CL, Morgan TK.

Reprod Sci. 2016 Nov;23(11):1575-1579. Epub 2016 May 11.

21.

Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.

Wagner AJ, Agulnik M, Heinrich MC, Mahadevan D, Riedel RF, von Mehren M, Trent J, Demetri GD, Corless CL, Yule M, Lyons JF, Oganesian A, Keer H.

Eur J Cancer. 2016 Jul;61:94-101. doi: 10.1016/j.ejca.2016.03.076. Epub 2016 May 5.

22.

A Multiplexed Amplicon Approach for Detecting Gene Fusions by Next-Generation Sequencing.

Beadling C, Wald AI, Warrick A, Neff TL, Zhong S, Nikiforov YE, Corless CL, Nikiforova MN.

J Mol Diagn. 2016 Mar;18(2):165-75. doi: 10.1016/j.jmoldx.2015.10.002. Epub 2015 Dec 30.

PMID:
26747586
23.

Utility of BRAF V600E mutation-specific immunohistochemistry in detecting BRAF V600E-mutated gastrointestinal stromal tumors.

Patil DT, Ma S, Konishi M, Carver PD, Pukay M, Beadling C, Corless CL, Rubin BP.

Am J Clin Pathol. 2015 Nov;144(5):782-9. doi: 10.1309/AJCPRK3V2EIIUPQZ.

PMID:
26486743
24.

SDHC methylation in gastrointestinal stromal tumors (GIST): a case report.

Urbini M, Astolfi A, Indio V, Heinrich MC, Corless CL, Nannini M, Ravegnini G, Biasco G, Pantaleo MA.

BMC Med Genet. 2015 Sep 28;16:87. doi: 10.1186/s12881-015-0233-7.

25.

Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity.

Hahn NM, Knudsen BS, Daneshmand S, Koch MO, Bihrle R, Foster RS, Gardner TA, Cheng L, Liu Z, Breen T, Fleming MT, Lance R, Corless CL, Alva AS, Shen SS, Huang F, Gertych A, Gallick GE, Mallick J, Ryan C, Galsky MD, Lerner SP, Posadas EM, Sonpavde G.

Urol Oncol. 2016 Jan;34(1):4.e11-7. doi: 10.1016/j.urolonc.2015.08.005. Epub 2015 Sep 9.

PMID:
26362343
26.

Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease.

Butler TM, Johnson-Camacho K, Peto M, Wang NJ, Macey TA, Korkola JE, Koppie TM, Corless CL, Gray JW, Spellman PT.

PLoS One. 2015 Aug 28;10(8):e0136407. doi: 10.1371/journal.pone.0136407. eCollection 2015.

27.

SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.

Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, Thomas CR Jr, Alberts SR, Dawson LA, Micetich KC, Thomas MB, Siegel AB, Blanke CD.

J Clin Oncol. 2015 Aug 20;33(24):2617-22. doi: 10.1200/JCO.2014.60.2219. Epub 2015 May 11.

28.

Hybrid Capture 2 is as effective as PCR testing for high-risk human papillomavirus in head and neck cancers.

Hooper JE, Hebert JF, Schilling A, Gross ND, Schindler JS, Lagowski JP, Kulesz-Martin M, Corless CL, Morgan TK.

Appl Immunohistochem Mol Morphol. 2015 Apr;23(4):266-72. doi: 10.1097/PDM.0000000000000036.

29.

The Signature Program: Bringing the Protocol to the Patient.

Kang BP, Slosberg E, Snodgrass S, Lebedinsky C, Berry DA, Corless CL, Stein S, Salvado A.

Clin Pharmacol Ther. 2015 Aug;98(2):124-6. doi: 10.1002/cpt.126. Epub 2015 May 11.

30.

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.

Carvajal RD, Lawrence DP, Weber JS, Gajewski TF, Gonzalez R, Lutzky J, O'Day SJ, Hamid O, Wolchok JD, Chapman PB, Sullivan RJ, Teitcher JB, Ramaiya N, Giobbie-Hurder A, Antonescu CR, Heinrich MC, Bastian BC, Corless CL, Fletcher JA, Hodi FS.

Clin Cancer Res. 2015 May 15;21(10):2289-96. doi: 10.1158/1078-0432.CCR-14-1630. Epub 2015 Feb 18.

31.

Novel mutations in neuroendocrine carcinoma of the breast: possible therapeutic targets.

Ang D, Ballard M, Beadling C, Warrick A, Schilling A, O'Gara R, Pukay M, Neff TL, West RB, Corless CL, Troxell ML.

Appl Immunohistochem Mol Morphol. 2015 Feb;23(2):97-103. doi: 10.1097/PDM.0b013e3182a40fd1.

PMID:
25679062
32.

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.

Lopez-Chavez A, Thomas A, Rajan A, Raffeld M, Morrow B, Kelly R, Carter CA, Guha U, Killian K, Lau CC, Abdullaev Z, Xi L, Pack S, Meltzer PS, Corless CL, Sandler A, Beadling C, Warrick A, Liewehr DJ, Steinberg SM, Berman A, Doyle A, Szabo E, Wang Y, Giaccone G.

J Clin Oncol. 2015 Mar 20;33(9):1000-7. doi: 10.1200/JCO.2014.58.2007. Epub 2015 Feb 9.

33.

Assessing copy number alterations in targeted, amplicon-based next-generation sequencing data.

Grasso C, Butler T, Rhodes K, Quist M, Neff TL, Moore S, Tomlins SA, Reinig E, Beadling C, Andersen M, Corless CL.

J Mol Diagn. 2015 Jan;17(1):53-63. doi: 10.1016/j.jmoldx.2014.09.008. Epub 2014 Nov 7.

34.

Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance.

Javidi-Sharifi N, Traer E, Martinez J, Gupta A, Taguchi T, Dunlap J, Heinrich MC, Corless CL, Rubin BP, Druker BJ, Tyner JW.

Cancer Res. 2015 Mar 1;75(5):880-91. doi: 10.1158/0008-5472.CAN-14-0573. Epub 2014 Nov 28.

35.

Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST).

Nannini M, Astolfi A, Urbini M, Indio V, Santini D, Heinrich MC, Corless CL, Ceccarelli C, Saponara M, Mandrioli A, Lolli C, Ercolani G, Brandi G, Biasco G, Pantaleo MA.

BMC Cancer. 2014 Sep 20;14:685. doi: 10.1186/1471-2407-14-685.

36.

Quadruple wild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways.

Pantaleo MA, Nannini M, Corless CL, Heinrich MC.

Cancer Med. 2015 Jan;4(1):101-3. doi: 10.1002/cam4.325. Epub 2014 Aug 28.

37.

Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract.

Tseng D, Kim J, Warrick A, Nelson D, Pukay M, Beadling C, Heinrich M, Selim MA, Corless CL, Nelson K.

J Am Acad Dermatol. 2014 Aug;71(2):229-36. doi: 10.1016/j.jaad.2014.03.033. Epub 2014 May 17.

38.

Mutation profiling in gallbladder cancer in Indian population.

Kumari N, Corless CL, Warrick A, Beadling C, Nelson D, Neff T, Krishnani N, Kapoor VK.

Indian J Pathol Microbiol. 2014 Jan-Mar;57(1):9-12. doi: 10.4103/0377-4929.130849.

39.

KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation.

Serrano C, Wang Y, Mariño-Enríquez A, Lee JC, Ravegnini G, Morgan JA, Bertagnolli MM, Beadling C, Demetri GD, Corless CL, Heinrich MC, Fletcher JA.

J Clin Oncol. 2015 Aug 1;33(22):e93-6. doi: 10.1200/JCO.2013.48.7488. Epub 2014 Mar 31. No abstract available.

40.

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.

Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, Blanke CD, Demetri GD, Heinrich MC, von Mehren M, Patel S, McCarter MD, Owzar K, DeMatteo RP.

J Clin Oncol. 2014 May 20;32(15):1563-70. doi: 10.1200/JCO.2013.51.2046. Epub 2014 Mar 17. Erratum in: J Clin Oncol. 2014 Oct 20;32(30):3462.

41.

Adoption of a clinical pharmacogenomics implementation program during outpatient care--initial results of the University of Chicago "1,200 Patients Project".

O'Donnell PH, Danahey K, Jacobs M, Wadhwa NR, Yuen S, Bush A, Sacro Y, Sorrentino MJ, Siegler M, Harper W, Warrick A, Das S, Saner D, Corless CL, Ratain MJ.

Am J Med Genet C Semin Med Genet. 2014 Mar;166C(1):68-75. doi: 10.1002/ajmg.c.31385. Epub 2014 Mar 10.

42.

Expression of FAP, ADAM12, WISP1, and SOX11 is heterogeneous in aggressive fibromatosis and spatially relates to the histologic features of tumor activity.

Misemer BS, Skubitz AP, Carlos Manivel J, Schmechel SC, Cheng EY, Henriksen JC, Koopmeiners JS, Corless CL, Skubitz KM.

Cancer Med. 2014 Feb;3(1):81-90. doi: 10.1002/cam4.160. Epub 2013 Nov 26.

43.

Gastrointestinal stromal tumors: what do we know now?

Corless CL.

Mod Pathol. 2014 Jan;27 Suppl 1:S1-16. doi: 10.1038/modpathol.2013.173. Review.

44.

Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer.

Barnett CM, Heinrich MC, Lim J, Nelson D, Beadling C, Warrick A, Neff T, Higano CS, Garzotto M, Qian D, Corless CL, Thomas GV, Beer TM.

Clin Cancer Res. 2014 Mar 1;20(5):1306-12. doi: 10.1158/1078-0432.CCR-13-1775. Epub 2013 Dec 18.

45.

Frequent PIK3CA mutations in radial scars.

Wolters KL, Ang D, Warrick A, Beadling C, Corless CL, Troxell ML.

Diagn Mol Pathol. 2013 Dec;22(4):210-4. doi: 10.1097/PDM.0b013e318288b346.

PMID:
24193002
46.

Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.

Ang DC, Warrick AL, Shilling A, Beadling C, Corless CL, Troxell ML.

Mod Pathol. 2014 May;27(5):740-50. doi: 10.1038/modpathol.2013.197. Epub 2013 Nov 1.

47.

Leiomyoma of the gastrointestinal tract with interstitial cells of Cajal: a mimic of gastrointestinal stromal tumor.

Deshpande A, Nelson D, Corless CL, Deshpande V, O'Brien MJ.

Am J Surg Pathol. 2014 Jan;38(1):72-7. doi: 10.1097/PAS.0b013e3182a0d134.

PMID:
24145645
48.

Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA.

Beadling C, Patterson J, Justusson E, Nelson D, Pantaleo MA, Hornick JL, Chacón M, Corless CL, Heinrich MC.

Cancer Med. 2013 Feb;2(1):21-31. doi: 10.1002/cam4.57. Epub 2013 Feb 3.

49.

Gastrointestinal stromal tumors: molecular markers and genetic subtypes.

Barnett CM, Corless CL, Heinrich MC.

Hematol Oncol Clin North Am. 2013 Oct;27(5):871-88. doi: 10.1016/j.hoc.2013.07.003. Epub 2013 Aug 26. Review.

PMID:
24093165
50.

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.

Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE.

J Clin Oncol. 2013 Sep 10;31(26):3182-90. doi: 10.1200/JCO.2012.47.7836. Epub 2013 Jun 17.

Supplemental Content

Loading ...
Support Center